Literature DB >> 20900

Effects of clozapine and other dibenzo-epines on central dopaminergic and cholinergic systems. Structure-activity relationships.

H R Bürki, A C Sayers, W Ruch, H Asper.   

Abstract

Structure-activity relationships of 16 dibenzoepines, including clozapine, loxapine, clothiapine and perlapine, have been investigated with regard to locomotor inhibition, cataleptogenesis, apomorphine antagonism, arousal inhibition, effect on striatal dopamine metabolism, and in vivo and in vitro anticholinergic potency. Thioridazine and the classical neuroleptics haloperidol and chlorpromazine were included in the study for comparison. The classical tests used to detect neuroleptic activity in laboratory animals were found to be poor predictors of possible clinical effectiveness of the dibenzo-epines.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 20900

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  5 in total

Review 1.  Antidepressant and antipsychotic agents.

Authors:  R A Lahti
Journal:  Naturwissenschaften       Date:  1979-08

2.  Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia.

Authors:  Amarendra N Singh; Cia Barlas; Huma Saeedi; Ram K Mishra
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

Review 3.  Clozapine, a fast-off-D2 antipsychotic.

Authors:  Philip Seeman
Journal:  ACS Chem Neurosci       Date:  2013-11-18       Impact factor: 4.418

4.  A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes.

Authors:  A N Singh; C Barlas; S Singh; P Franks; R K Mishra
Journal:  J Psychiatry Neurosci       Date:  1996-01       Impact factor: 6.186

5.  Post-synaptic 5-HT1A receptor involvement in yawning and penile erections induced by apomorphine, physostigmine and mCPP in rats.

Authors:  P Protais; M Windsor; E Mocaër; E Comoy
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.